Q-omics provides the consensus-scored CCT6P3 profile across patient tissues and cancer cell-line models. CCT6P3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CCT6P3 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, CCT6P3 RNA expression shows 20,128 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, HNSC, and UVM as cancer lineages where CCT6P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCT6P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCT6P3 survival associations across molecular data types. CCT6P3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCT6P3 RNA expression–survival associations across cancer types. High CCT6P3 expression shows unfavorable associations in ACC, KIRC, LGG, LIHC and MESO, but favorable associations in UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CCT6P3 RNA expression.
This table summarizes CCT6P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CCT6P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCT6P3 shows higher tumor expression in HNSC, COAD, KIRC, LIHC, CHOL and BLCA. The HNSC box plot shows higher CCT6P3 RNA expression in tumor versus normal tissue (log2 FC = +0.411, t-test p < 0.001).
This table shows molecular features associated with CCT6P3 in patient tissues and cancer cell lines. In patient samples, CCT6P3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
